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INTRODUCTION
This report provides an overview of the presentations and discussions emerging from a Provider
Workshop on ARV-Based HIV Prevention for Women: State of the Science and Considerations for
Implementation in Zimbabwe convened by the Ministry of Health and Child Care (MOHCC) and the
Population Council in Harare in May 2014.
The workshop in Zimbabwe is part of a broader global process to begin paving the path for microbicides
introduction while awaiting the results of the ongoing confirmatory trial (FACTS 001) of tenofovir gel
in South Africa. USAID is spearheading a global effort towards a “Shared Vision and Strategic Plan for
Microbicide Introduction.” To learn about potential models of introduction,
the development of a strategic decision-making and planning tool was considered a priority.

I. Background
After 20 years of microbicides research in which half a dozen products were tested in large-scale trials
that yielded negative or equivocal results, 1% tenofovir gel (TFV) has been the first vaginal microbicide gel
to show promise. Tenofovir, a nucleotide reverse transcriptase inhibitor (NRTI) used orally for treatment,
was tested as a vaginal gel formulation by the Centre for AIDS Programme of Research in South Africa
(CAPRISA) in the CAPRISA 004 trial [Abdool-Karim et al., 2010]. The randomized, placebo-controlled,
double-blind trial demonstrated that women assigned to 1% TFV gel had a 39% lower risk of HIV infection
compared with women in the placebo arm. In addition, the gel was even more protective for women who
used it in more than 80% of sex acts; in these high adherers, reduced risk of HIV was 54% [Abdool-Karim
et al., 2010].

A toolkit for strategic decision-making and planning for microbicides
With the support of USAID/Washington, the Population Council has been engaged in the development and
testing of a Toolkit for Strategic Decision-Making and Planning for Microbicides. The toolkit was designed
to assist policymakers and programme managers to plan for the introduction and initial roll-out of TFV gel
or other ARV-based HIV-prevention technologies (and accompanying services) within existing programmes
in a manner that supports high-quality integrated services and explicitly takes into account the
epidemiologic context and capacity of the health system, whatever the setting. The toolkit is being piloted
in India and Zimbabwe but is designed to be applicable to introducing a wider range of prevention
technologies. The toolkit consists of three modules:
Module 1. Landscape Analysis: An analysis of the epidemiologic context of the HIV epidemic, along with
an HIV policy and programme scan. This consists primarily of a desk review of available literature and
data, supplemented as needed with input from experts familiar with the HIV epidemic and the specific
country context.
Module 2. Discussion Guide for Key Opinion Leaders (KOLs) and Decision-Makers: A guide to conducting
in-depth interviews (IDIs) with a small group of key decision-makers who will be involved in or influence
strategic decisions about the introduction and roll-out of TFV gel. Results will provide an indication of the
strategic role TFV gel could play within a country’s HIV-prevention programme and help determine how
best to continue to explore and plan for introduction.
Module 3. Programme Planning Guide: The Module 3 tool is to be used with providers and programme
managers to consider service design for product introduction. Module 3 guides workshop participants to
consider the feasibility of introducing HIV-prevention tools, including TFV gel, in specific facility-based
settings. It guides users through a series of design considerations to determine opportunities and
1

challenges in service setting(s) that should be addressed in programme planning. A “facility checklist” to
be used in tandem with Module 3 was also developed.

The HIV landscape in Zimbabwe
With a prevalence rate of 15% [ZIMSTAT/ICF, 2012], Zimbabwe has a generalized HIV epidemic in which
heterosexual intercourse accounts for 93.95% of infections [ZIMSTAT/ICF, 2012]. Vertical transmission
(from mother to child) is the second most common route of transmission, accounting for 5% of infections
[NAC/UNAIDS/World Bank, 2011]. In 2009, women and girls represented 56% of the 1.6 million people
living with HIV. Young women are disproportionately affected: infection rates among 15–24-year-old
females are approximately three times higher than in males of the same age [UNAIDS, 2010].
Given the feminization of the epidemic, where prevalence in women aged 15–49 years is 18% compared
with 12% among men aged 15-49 years, there is a great need for vaginal microbicides or other femalecontrolled methods that women can use to help reduce their risk of HIV infection. Clinical trials of vaginal
microbicides have been conducted in Zimbabwe since the 1990s. Zimbabwe is a key country in subSaharan Africa with a generalized epidemic and a commitment to microbicide introduction.

II. Rationale for a workshop focused on providers and programme managers
Recognizing the important gate-keeping role that service providers and programme managers play in
fostering, or impeding, access to new HIV-prevention tools, their approval and “adoption” is critical for the
success of any product. Gathering their insights about service-delivery strategies to incorporate HIVprevention technologies was deemed essential. Specifically, the workshop sought to obtain providers and
program mangers’ input into the design of appropriate services for tenofovir gel, should it be introduced
into the country.
The workshop was preceded by a series of in-depth interivews with KOLs in Zimbabwe, the majority of
whom suggested that working directly with programme managers and providers was a critical next step in
preparing health systems for product introduction. Although some KOLs were concerned about
widespread communication with the public before results of the FACTS 001 confirmatory trial are
available, the majority recommended bringing providers into the discussion earlier rather than later.

Workshop objectives
o

To explore the feasibility of new HIV-prevention product introduction in diverse service-delivery
settings through dialogue with health service providers;

o

To gather input from programme managers and representatives of provider professional
associations (i.e., nurse/midwives, OB/GYNs, pharmacists, etc.) about a range of programmatic
issues related to introducing HIV-prevention products for women, including TFV gel if proven
effective.

Participants
The workshop brought together 78 participants representing the spectrum of agencies engaged in HIV
prevention in Zimbabwe, including: health service providers from 10 districts, civil society representatives,
researchers, international NGOs, academics, and others.

2

III. Presentations—Summary and Key points
This section provides a summary of selected presentations and key points emerging from discussions at
the workshop.
Welcome and Official Opening (Dr. Tsitsi Apollo, Deputy Director HIV/AIDS and STIs, Zimbabwe Ministry of
Health and Child Care)
The workshop was officially opened by Dr. Tsitsi Apollo who provided welcoming remarks and
acknowledged the broad range of participants and institutions at the workshop. Dr. Apollo acknowledged
financial support from USAID as well as technical support from the Population Council and reiterated the
Ministry’s openness to dialogue and partnership in addressing challenges affecting the health sector.Dr.
Apollo stressed that the overall 15% HIV prevalence in Zimbabwe remains unacceptably high and that
data showing the heightened vulnerability of women and girls to HIV infection confirms the need for
dialogue on prevention options for women. Evidence from the ZDHS (2010-11) shows that among women
aged 15-49, prevalence is 18% compared with 12% among men aged 15-49. Figure 1 shows HIV
prevalence by age and the disparity in prevalence rates for women and men, as indicated by the ZDHS
2010-11.
Figure 1: HIV Prevalence by Age and Sex

Source: ZIMSTAT and ICF International, 2012. Demographic and Health Survey (DHS)

Dr. Apollo reminded workshop participants of Zimbabwe’s key role in the microbicide field through active
engagement and pioneering work in research and clinical trials. She noted that Zimabwe should not lag
behind on implementation. Given that ARV-based prevention requires periodic HIV testing, efforts to
strengthen health systems’ capacity to provide testing and re-testing will be needed. Various models of
testing, including home-based testing, will need to be tested to determine their feasibility and
acceptability. Currently, Zimabawe plans to pilot test different models.
The Need for New HIV-Prevention Methods and Combination HIV-Prevention Strategies (Ms. Gertrude
Ncube, MOHCC)
Ms. Ncube’s presentation described the Combination HIV-Prevention Strategy that Zimbabwe developed
and is implementing. This is the strategic framework within which dialogue on introducing ARV-based
prevention tools/products should be framed. Combination prevention was defined as “...rights-based,
evidence-informed, and community-owned programmes that use a mix of biomedical, behavioural, and
3

structural interventions, prioritized to meet the current HIV-prevention needs of particular individuals and
communities, to have the greatest sustained impact on reducing new infections.” Combination prevention
has been prioritised in Zimbabwe due to: 1) the realization that there is no single “magic bullet” for HIV
prevention; 2) the need to optimize combined effects of interventions; 3) the importance of offering
different options to people; and 4) the efficiencies of integrated delivery. As shown in Figure 2,
combination prevention is underpinned by coordinated behavioural and biomedical strategies for HIV
prevention.
Figure 2: Zimbabwe Combination HIV-Prevention Strategy Priorities

Ms. Ncube outlined the “HIV transmission highway,” based on evidence from the Modes of Transmission
(MoT) study, which cited: serial casual relations, frequenting sex workers, high levels of STIs (in particular
HSV-2), cross-generational sexual relations, mother-to-child transmission (MTCT), and early sexual debut
as contributing towards HIV transmission. Multiple concurrent partnerships (MCP), combined with low
condom use and low risk perception among those in long-term relationships, as well as low levels of male
circumcision are additional factors.
While there has been a decline in HIV prevalence worldwide as a result of behaviour-change interventions,
preventing HIV infections remains the most important measureof controlling the epidemic. It is crucial to
direct efforts towards interventions that are appropriate to the type of epidemic in each setting. As new
evidence emerges, support of new interventions will be needed; these may include pre-exposure
prevention (PrEP) as part of combination HIV prevention. Existing HIV-prevention interventions are shown
in Figure 3, illustrating that microbicides for women (noted in white) remain a missing piece in the menu
of interventions.
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Figure 3: Overview of Prevention Interventions

New HIV-Prevention Methods and Combination HIV Prevention with a Focus on PMTCT (Dr. Tonderai
Murimwa, UNICEF)
Dr. Murimwa outlined the epidemiology of HIV in Zimbabwe and described relevant maternal, neonatal,
and child health (MNCH) indices. An estimated 156,718 children 0-14 years are living with HIV in
Zimbabwe; the MTCT rate was estimated at 18%. The Elimination of MTCT Strategy, PMTCT Programme
results of 2013, and Option B+ for PMTCT programmes were presented.
The Zimbabwe prevention of mother-to-child transmission (PMTCT) package of care includes antenatal
care, universal HIV counselling and voluntary testing, partner involvement in counselling, provision of
antiretroviral (ARV) prophylaxis, safe delivery, postnatal care for infants, and counselling on safe
breastfeeding practices. MNCH indices based on ZDHS (2010-11) findings concluded that 90% of
pregnant women received antenatal care (ANC) (ZDHS 2010-11)1. An estimated 43% of women reported
attending a postnatal care (PNC) visit by six weeks, which presented a missed opportunity for PMTCT.
Nearly one-third (31%) of children are reported to be exclusively breastfed. The Option B+ strategy is
based on the recommendation that all HIV-positive pregnant and breastfeeding women should initiate
triple ARVs (ART), which should be maintained at least for the duration of MTCT risk. In addition, women
meeting treatment eligibility criteria should continue lifelong ART. Option B+ treatment involves triple
ARVs (ART) for life for any woman diagnosed HIV-positive in pregnancy irrespective of WHO clinical stage
or CD4 count. Despite the benefits of Option B+, some issues remain, including: readiness and
willingness to adhere to lifelong ART (women must not feel ‘’coerced’’ to be on lifelong ART);
inconvenience of lifelong treatment; cost to the programme; risks of ART-toxicity, resistance, or drug
interactions. It was noted, however, that improvements in potency, toxicity profile, and tolerability
(including reduced pill burden) allow for durable viral suppression for most patients.

1

First trimester (3 months)—19%, average gestational age at booking is 25 weeks (6 months+) and 4 or more ANC visits—65%.
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Overview of Future ARV-Based Products: Microbicide Gels and Vaginal Rings (Professor Mike Chirenje, UZUCSF))
This session provided the audience with a technical update on ARV-based gels and rings, emphasizing the
ongoing trials in South Africa and Zimbabwe and timelines for results, including potential benefits in the
Zimbabwean context. Dr. Chirenje provided an overview of the types of microbicides in development and
on the horizon, as well as a review of ongoing research on their safety and efficacy. The history of
microbicide development starts with the 1st generation surfactants, 2nd generation polymers, 3rd
generation ARVs, and leads up to the 4th generation receptor blockers. Some of this history is shown in
Figure 4. Multiple products have been tested over nearly two decades, leading up to the landmark results
of the CAPRISA 004 1% tenofovir gel trial in 2010.
Figure 4: Microbicides Evolution
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Topical microbicides under development can be in
the form of a cream, suppository, film, or gel.
Currently, tenofovir (TFV) gel is being used in the form
of a 1 ml intravaginal dose providing 40 mg of TFV.
CAPRISA 004 (Centre for AIDS Programme of
Research in South Africa) was a Phase 2b trial in
South Africa that tested the safety and effectiveness
of 1% tenofovir gel for the prevention of HIV in
women. The trial used the BAT 24 regimen that
requires women to insert the gel up to 12 hours
before sex or as soon as possible within 12 hours
after sex. The results showed 39% gel effectiveness,
while additional results showed the gel as even more
effective with greater adherence to the regiment.
There was a 54% reduction in HIV among women who
followed the regimen most closely. Importantly, no
resistance to tenofovir was identified. The gel was
also found to be safe in Hepatitis B–infected women.
The study found no evidence of risk compensation or
behavioural disinhibition. There was also a 50%
decrease in HSV-2 infections among the women who
were randomized to the tenofovir gel cohort.
After the CAPRISA 004 trial, the VOICE (Vaginal+Oral
Interventions to Control the Epidemic) study was
conducted in South Africa, Uganda, and Zimbabwe.
VOICE was a Phase 2b, randomized, double-blind,
placebo-controlled, five-arm trial of daily use of
vaginal 1% TFV gel, oral TFV (TDF), and oral
tenofovir/emtricitabine. The VOICE study did not
confirm the CAPRISA 004 result of 39% protection.
Another study of 1% tenofovir gel, FACTS 001 (Follow
on Consortium on Tenofovir Studies) is underway in
South Africa, with results expected in early 2015.
Additional Technologies
Dr. Chirenje noted current efforts to test the efficacy
of various other HIV-prevention technologies,
including the dapivirine intravaginal ring. The ring is
being tested in South Africa and Uganda, and at
Microbicide Trials Network (MTN) study sites in
Malawi, South Africa, Uganda, and Zimbabwe. In
addition, an HPTN 076 study will evaluate the safety
of an injectable product (TMC278 LA; 1,200 mg dose)
in women in sites in sub-Saharan Africa and the
United States. Dr. Chirenje concluded with a brief

Questions and Answers
Selected questions from workshop participants:



Question: What are the effects of tenofovir on pregnancy and
lactation?
Response: No transfer of tenofoivir from the placenta to the
baby was seen in previous trials.



Question: Does the ring have an applicator?
Response: The ring does not have an applicator. It has been
designed to be inserted by the fingers, similar to the female
condom.



Question: Does it stay in place? What happens during
menstruation and intercourse?
Response: The ring stays in place, including during
intercourse. It is made from silicone and most men can
hardly feel it.



Question: How are we dealing with women who are taking
placebos?
Response: This is a randomized controlled trial (RCT) in
which a researcher does not know which women are using a
placebo or the actual product. However, the women are told
beforehand that they are getting an active or a nonactive
ring.



Question: Why was Harare chosen as a site (Spilhaus Clinical
Research Site) and why were samples from rural areas not
selected?
Response: It is complex to set up a research site. It requires
elaborate tests and involves a complex process; hence the
decision to choose Spilhaus was based on the capacity.



Question: What are the cost implications for women?
Response: Effort is being made internationally to make the
product available to “ordinary” women.



Question: What has been women’s take on the issue of dry
sex and use of the gel?
Response: Actually it seems from the studies that people
actually prefer more lubrication rather than dry sex. However,
generally women tend to over clean the vaginal area, which
leaves it too dry and vulnerable.



Question: What interventions are there with regard to women
getting infected during the time they are breastfeeding their
infants?
Response: All mothers are tested when registering for the
antenatal clinic. After that they get tested three times.



Question: What is the HIV status of the men and women who
are in these studies?
Response: We enroll men and women who are negative and
monitor them if they acquire the virus during the trial.



Question: Are these gels all-encompassing or do we also
need to stress the use of condoms?
Response: It would be unethical to enroll women in the study
and not give them access to condoms since condoms are
tried and tested.



Question: How do you measure the efficiency of the ring?
Response: We use randomization, i.e., if everything is the
same except an active or inactive ring, then the only answer
is the ring.



Question: It seems men are a stumbling block. What are we
doing to involve them?
Response: We always encourage our participants at the
beginning to involve their partners in the studies. 7

reflection on the timeline and investments made so far towards an anti-HIV vaccine.
Key Opinion Leader Insights: Results from Zimbabwe Study (Dr. Saiqa Mullick, Population Council)
Dr. Mullick reported on the results of a qualitative study among KOLs in Zimbabwe. The objective of the
study was to gather perspectives on key policy and programmatic issues to inform the introduction of 1%
tenofovir gel should it be shown effective. A total of 18 in-depth interviews with leading opinion leaders in
Zimbabwe were conducted using a standardized discussion guide and analyzed by the Population Council
research team. The opinion leadersrepresented a broad swath of stakeholders including government,
regulatory agencies, NGOs, academia, civil society, professional associations, and donor agencies.
Selected findings regarding key themes are presented here.
Efficacy
Most respondents believe that a “recommended level of efficacy” should be reached before approval of
TFV gel. A few felt that “any level of efficacy would be sufficient,” given that there is no currently available
ARV-based prevention option for women. About one-third believe that the gel would not be worth
introducing unless it is at least 50–60% effective, comparable to male circumcision; a few were of the
opinion that the 39% level of efficacy shown in the CAPRISA 004 trial would be sufficient.
Safety
The majority of respondents believe that TFV gel for HIV prevention is important, but that product safety is
of paramount importance. Concern about safety of the gel in different populations, for example, in
pregnant women and in adolescents, was voiced by several respondents. Some recommended that
separate safety studies among adolescents be conducted. Most respondents were not concerned about
(or did not mention) fertility as an issue, although two noted that any impact on fertility would limit uptake.
Intended users
From a public health and cost-effectiveness standpoint, most respondents felt that TFV gel would yield
optimum results if focused on women at highest risk, especially young women, sex workers, married
women who are unsure of husband’s status, and women with multiple partners. In addition, serodiscordant couples were identified as a potential user group, although identifying such couples was
considered by many to be challenging. The majority of respondents identified young women as a high-risk
group, given that HIV incidence is highest among the 20–24-year-old age group, thereby making them a
logical priority for tenofovir gel.
Where should tenofovir gel be offered?
Respondents stressed that tenofovir gel should be available in both the public and private sector and
recommended that distribution should start through primary health centres (PHCs) and nongovernmental
organisations (NGOs). Another recommendation was to ensure the gel be introduced through both family
planning/sexual and reproductive health (FP/SRH) services and HIV-prevention programmes. Placing
tenofovir gel within primary health or SRH services was viewed as less stigmatizing and more routine.
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Lessons learned from past and current HIV-prevention programmes, advocacy, and community
engagement activities (Dr. Joconiah Chirenda, University of Zimbabwe, Community Medicine)
This presentation provided historical background on infectious-disease prevention and control, chain of
infection, and HIV prevention. The focus was on the importance of surveillance and response, which
facilitates detection, investigation, and monitoring of infections. Prevention and control of infectious
diseases requires applied research, infrastructure, and training. Dr. Chirenda highlighted the importance
of building on existing infrastructure to generate prevention and control strategies that are context
specific, and the need to learn from interventions from other programmes. He called for the building of
multidisciplinary teams of social scientists, health economists, clinicians, public health practitioners, and
civil society to examine new technologies and interventions before their adoption.
The Policy Environment in Zimbabwe (Mr. Amon Mpofu, National AIDS Council)
This presentation highlighted Zimbabwe’s constructive policy environment with respect to HIV and AIDS.
The National AIDS Trust Fund was described as a model for resource mobilization. Mr. Mpofu noted that
new interventions proven to be efficacious have received support from Parliamentarians, citing the
example of voluntary medical male circumcision (VMMC). Due to the favourable policy environment and
strong partnerships, the National AIDS Council (NAC) has managed to survive in an economically
constrained context and has achieved good results. NAC’s role in product introduction would likely involve
disseminating information on the product after proper authorization, and ensuring that products are
integrated into existing HIV-prevention programmes.
Widening the scope of Family Planning to include HIV-prevention strategy (Dr. Edmore Munongo, ZNFPC)
Dr. Munongo noted that the family planning (FP) programme in Zimbabwe, begun in 1953 by volunteers,
has expanded tremendously over the past 30 years. He provided background on the Zimbabwe National
Family Planning Council (ZNFPC), established in 1985. ZNFPC is supported by the MOHCC, IPPF, UNFPA,
NAC, DFID, USAID, Crown Agents, PSI, PSZ, UZ, MCHIP, and UNICEF. Key programmes run by ZNFPC
include: 1) community-based distributor (CBD) programme; 2) adolescent sexual and reproductive health
(ASRH); 3) Delivery Team Top Up (DTTU); 4) training, marketing, and communication; 5) evaluation and
research, along with overall support to the health sector.
Through its FP programmes, ZNFPC has made important contributions to the HIV response, although gaps
remain. There is still an unmet need for family planning, particularly among adolescents and those hard to
reach. ZNFPC faces challenges including limited funding, high staff attrition, low uptake of permanent FP
methods, and limited storage space for FP commodities, among others. Dr. Munongo concluded with
recommendations on intensifying advocacy on the importance of RH/FP in improving maternal and child
health, reduction of HIV and poverty alleviation, integration of RH/FP and HIV/AIDS to ensure
comprehensive services, support of effective community-based interventions to increase access to
services as well as prioritising policy support to improve access to RH/FP services, particularly access by
vulnerable groups and in particular youth and HIV-positive people.

IV. Insights from the thematic breakout groups
Following these presentations by leading experts, the meeting was organised around critical themes that
were reviewed and debated in breakout groups. During lively discussion and debate, meeting participants
worked to identify key issues related to key populations, potential product access and service delivery
9

channels, provider-related issues, and the larger policy environment. Each breakout session led to robust
discussions, the results of which are briefly highlighted below.

1. Potential user groups and their needs
Participants felt that TFV gel has clear benefits in terms of reducing risk, providing women with an option
under their control, and offering the conveniencece of use only when needed. The gel is likely to benefit
many types of women including: married women, sex workers, adolescents,and women in sero-discordant
relationships. Essentially, the group felt that all sexually active women “at risk” would potentially benefit.
There was considerable discussion around the possibility of marketing the gel to men and learning more
about men’s perspectives.
The potential barriers to introduction of TVF gel were identified as: lack of knowledge by users, discomfort
with testing, concerns around stigma, cost (especially in the context of high levels of poverty), limited
provider knowledge, negative provider attitudes, community perceptions, product availability and supply
chain issues, and challenges related to adherence.

2. Product access and service-delivery models
There was a general diccusion around the need to strengthen health systems’ capacity to provide HIV
testing and re-testing. Participants suggested several possible delivery models for TFV gel, including the
following.
PMTCT and ANC services are considered important entry points given that women are already accessing
these services. Adding microbicides information—and, as appropriate, product—could provide an
integrated approach to service delivery.
Voluntary Testing and Counseling Centres could play a pivotal role, as they have an existing servicedelivery infrastructure. These centres provide scope to work with a variety of organisations with potential
distribution networks.
Youth Service Centres currently distribute commodities (condoms) and could potentially add TFV gel to
that existing distribution network, as and when appropriate.
The group also considered potential challenges for introduction. For example, adding a new product into
health services can tax an already overburdened workforce. The required testing could pose challenges,
as clients may be averse to retesting in order to get resupply of gel. Home testing remains controversial
because modalities around counselling are yet to be defined. However, it was noted that the government
will conduct pilot studies to determine the feasibility of home testing. Participants further noted that
stigma and discrimination may pose a problem, as communities may have negative (and/or ill-informed)
perspectives about the gel.
Finally, it was noted that the Ministry of Health has an Advocacy and Communication Strategy that
facilitates communication from the grassroots to Parliamentarians; that strategy could be used to
disseminate information on new technologies. In addition, there is a need to focus on leveraging existing
approaches for demand creation.
The group recommended:



Training of health workers and distributors on use of the gel
Working with partners, such as ZNFPC and NAC, as well as organisations providing VCT and
PMTCT services




A phased-introduction approach
Prioritizing integration within existing strategies.
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3. Provider-related issues
An almost unanimous call was made for training of service providers so they can understand the complex
issues concerning the gel. It was noted that the confidence of potential users could be affected if service
providers cannot provide sufficient information about the gel. Provider competency in communicating the
notion of “partial protection” was seen as important. Participants suggested that training should focus on
both developing competencies and transforming attitudes. Negative provider attitudes can be a barrier to
provision and, consequently, client uptake. This is especially true in the case of products that may be
provided to stigmatized groups, such as sex workers. Participants further emphasized the need to focus
on both demand- and supply-side components as it could be counterproductive to create demand for a
product that is not yet available, and it is difficult to invest in supplying product where demand is low.
The group underscored that service providers for TVF gel should not be too dissimilar from those in the
existing structure, particularly since product introduction should encourage and prioritize integration.
Given that TFV gel is a medical product, it should be handled by professionals who are able to provide
accurate information; nurses, doctors, village/community health workers, and possibly pharmacists, were
identified as the most appropriate service providers.
Several questions emerged relating to how other sexual and reproductive health issues will be addressed.
Given that TFV gel does not provide dual protection, the group felt it was imperative that the gel be used
together with contraceptive method to protect against pregnancy. Questions arose around whether
women can use the gel while menstruating or wearing a diaphragm. It was clear that service providers will
need adequate training to be able to disseminate correct information.

4. Policy environment and advocacy
It was noted that Zimbabwe has a robust policy environment that should be appropriately used for
product introduction. The Medicines Control Authority of Zimbabwe is a key institution that should be
involved in review and approval prior to full-scale rollout. It was noted that there are several strategic
documents that a new product can build upon, and there is further scope to integrate product information
into the curricula of health professionals’ trainings. Participants emphasized that research will be critical
for successful product implementation and that it should focus on product acceptability within the
Zimbabwean context as well as on monitoring drug resistance, especially because there has not been
sufficient evidence around whether use of TFV gel heightens the possibility of drug resistance.
Operational research was considered of high importance and high priority in the process of introducing
any new ARV-based product such as TFV gel. Distribution and use of the gel should be planned based on
the current context and with a focus on complementing existing HIV-prevention interventions.

V. Priority-Setting Exercise
An important component of the workshop was to generate discussion and input around next steps and
key activities, particularly from the point of view of service providers (i.e., nurses, medical officers). Most
of the service providers (N=46) in the workshop participated in this exercise. After the thematic breakout
sessions, workshop participants were led through a priority-setting exercise. First, participants were asked
to create a list of key activities for introduction of TFV gel. They were asked to consider which activities
were of most importance and which they felt should be given high priority. A comprehensive listing of
activities and potential next steps was generated. Figure 5, visually depicts the range and type of
activities identified.
Identifying and Prioritizing Activities for Introduction

Participants were then asked to define and order activities in terms of importance and priority. While most
of the activities were considered important by the majority of respondents, a few were mentioned multiple
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times and continued to emerge in the discussions. For example, almost half felt that sensitization of
women, providers, and civil society about the gel was of high importance and a high priority. Health
worker training was also considered to be of high importance and high priority by many. Interestingly,
research (operational, clinical, and implementation science) was cited by almost all (40) providers as
being of high importance and high priority in the process of introducing the gel. The three key areas are
depicted in the center circle of this graphic.
Figure 5: Priority Activities for Introducing Tenofovir Gel

Feedback on Potential User Groups
Another exercise was to identify and prioritize potential user groups. Service providers outlined user
groups they felt would be of importance and priority when introducing TFV gel. Again, while a very broad
array of potential users were listed, as noted in the outermost circle of the graphic, a few groups emerged
as being both important and a priority. Adolescents were cited as the group that was most important,
followed by sex workers. Sex workers were cited as being of highest importance and highest priority by
half of the providers. Married women and women in sero-discordant partnerships were also cited as being
of high importance and high priority. Figure 6 below depicts the broad range of potential user groups
identified by providers.The key populations considered most important were commercial sex workers,
married women, discordant couples, and adolescents/young women.
12

Figure 6: Potential User Groups

Top Line Suggestions from Workshop Participants
Throughout the day-and-a-half workshop, insights and information were gleaned from meeting
participants. A short, self-administered questionnaire was given to providers at the end of meeting. A brief
summary of findings can be found in Appendix 1.
Also as part of the workshop, we requested feedback from providers on a facility checklist that had been
developed by the Population Council as part of the broader microbicide toolkit. The tool generated lively
discussion. Provider feedback on the facility checklist is summarized in Appendix 2.
Finally, we asked participants for their top suggestions around product introduction. The chart that follows
outlines the key suggestions offered by workshop participants.
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SUGGESTIONS FROM WORKSHOP PARTICIPANTS ON POTENTIAL PRODUCT INTRODUCTION
Focus on integration. Although the products are new, they should add to the existing HIV-prevention package,
building on existing HIV-prevention models. Successful introduction and uptake will largely depend on the costeffectiveness of the products, and leveraging existing structures and systems provides scope for achieving
optimum results.
Be guided by existing frameworks. The current policy framework around access to information on and
commodities for HIV prevention must determine who should access the product and how. In addition, the
policy framework should provide sufficient guidance on testing as well as availability and accessibility.
Prioritize availability, accessibility, and affordability (Three As). If a product is proven efficacious, there should
be investments to ensure its availability and accessibility to those who need it most. It must be made
affordable to targeted groups.
Invest in efforts to determine acceptability of products. There have been some acceptability studies that have
concluded the products are acceptable, but these have primarily focused on acceptability within research
settings. Full-scale product rollout should be informed by acceptability within the contexts where the product is
expected to be used.
Employ a phased approach. Successful introduction will be based on a combination of factors and appropriate
staging and sequencing of activities. A phased approach will ensure buy-in and policy support, positive provider
attitudes, uptake willingness by women, male support, and supportive communities.
Define and communicate the role of civil society. Civil society has a significant role in the response to HIV in
Zimbabwe. Similarly, civil society is likely to play a key role around new product communication, demand
generation, and stigma reduction.
Address negative attitudes by health providers. Health providers will play a key role in supporting successful
introduction of the product. Positive attitudes by health providers towards the products will likely result in
successful uptake.
Utilize lessons from VMMC and other interventions. A new product will be introduced into a context where other
interventions have been successfully introduced. Opportunities for leveraging lessons from VMMC, treatment
as prevention (TASP), female condom, other SRH interventions will be important, especially with respect to
ensuring messages are well segmented and clearly communicate the protective effect.
Communicate appropriately for targeting and segmentation. The product will be made available to different
age groups and populations with different characteristics. Communication messages and mediums should be
guided by solid evidence and should address the information needs of specific groups using the most
appropriate communication mediums.
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VII. Conclusion
Zimbabwe can build upon its policy and scientific capacity to determine whether tenofovir gel can offer
added benefits relative to costs within the evolving context of combination prevention. Both biomedical
and behavioural interventions will be needed. On the biomedical side, interventions, including relatively
new approaches such as MMC, TASP, and oral PrEP, are currently underway. Overall there was general
broad support from stakeholders for tenofovir gel as an HIV prevention technology, pending positive
results of the FACTS 001 trial. lf Zimbabwe determines that tenofovir gel would be a useful addition to its
HIV prevention programme, pilot demonstration projects will be critical to determine the most strategic
entry points for introduction. Zimbabwe’s momentum in curbing the HIV epidemic, experience with new
technologies and clinical trials, and its capacity for operations research makes it a conducive setting for
designing and conducting the necessary demonstration projects.
The workshop was successful in stimulating discussion among service providers and programme
managers who would have responsibility for implementation of TFV gel if it were approved. The workshop
guided participants through a set of service design considerations and questions which must be
addressed in any future introduction planning. Engaging providers in the discussion and gathering their
input around service design is a critical step towards developing a programmatic action plan, which is a
logical next step once results of ongoing research are available.
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APPENDIX 1: Workshop Agenda

ARV-Based HIV Prevention for Women:
State of the Science and Considerations for Implementation
Provider Workshop/Zimbabwe Consultation
27-28 May 2014
AGENDA
Objectives:
1. Review the state-of-the-evidence around topical PrEP as HIV prevention tool for women
2. Present findings from the Key Opinion Leader Study
3. Facilitate discussion and feedback on potential service delivery channels, user groups, and
approaches for introduction of topical PrEP or other microbicides
DAY 1: Tuesday, May 27
8:30 a.m.

Coffee and Registration

9:00-9:20 a.m.
Welcome and Introductions (Dr. Owen M. Mugurungi)
Welcome participants and thank them for their time, review meetings goals, objectives, and
agenda. Comment on the state of the HIV epidemic and prevention in Zimbabwe and this meeting
intended to promote discussion around topical PrEP and microbicides.
9:20-9:40 a.m.
The Need for New HIV Prevention Methods and Combination HIV Prevention (Dr.
Tonderai Murimwa)
Present rationale for developing and implementing new HIV prevention methods, in particular
women-initiated methods. Briefly review HIV prevention methods currently available – focus on
PMTCT. Clarify that this meeting will only cover Topical PrEP recognizing that those methods
are part of a larger HIV prevention strategy.
9:40-10:00 a.m.
The Need for New HIV Prevention Methods and Combination HIV Prevention (Ms.
Gertrude Ncube)

TASP, VMMC, PEP, oral PrEP. Clarify that this meeting will only cover topical PrEP
recognizing that those methods are part of a larger HIV prevention strategy.
10:00-10:30 a.m.
Overview of Future Potential ARV-Based Products: Microbicide Gels and Vaginal Rings
(Dr. Mike Chirenje)
Provide an overview of microbicide clinical trial findings and ongoing clinical trials, and
potential benefit of these technologies. Speaker will give a technical update on ARV-based gels
and rings, emphasizing the ongoing trials in South Africa and Zimbabwe and timelines for
results, including their potential benefit in the Zimbabwean context.
10:30-11:00 a.m.
Discussion (Facilitator: Dr. Murimwa)
11:00-11:15 a.m.

Tea Break

11:15 a.m.-12:00 p.m.
Insights from Key Opinion Leaders in Zimbabwe: Results of a Qualitative Study (Dr.
Saiqa Mullick, Population Council)
Provide overview of the Population Council’s work to prepare for Microbicide Introduction and
Access, under global USAID funding on microbicide preparedness. Present findings from a
qualitative study of Key Opinion Leaders in Zimbabwe.
12:15-12:30 p.m.
Discussion (Facilitator – Dr. Samu Dube)
12:30-1:30 p.m.

Lunch

Afternoon Session
Begins with panel on lessons learned from past or current product introduction efforts related to
HIV and/ or SRH more broadly.
1:30-2:30 p.m.
Panel: Dr. Joconiah Chirenda, Dr. Edmore Munongo, Ms. Dagmar Hanisch, Mr. Raymond
Yekeye
This expert panel will provide an overview of lessons learned from past and current HIV
prevention programs, and what advocacy and community engagement activities have been
undertaken to date. Panelists will present findings/insights from experiences related to the
introduction of other prevention products from SRH and HIV
2:30-2:45 p.m.

Discussion

2:45 p.m.

Introduction to Breakout sessions: Goals, Process, Expected
Outcomes, Tools (Ms. Ravikanthi Rapiti, Population Council)
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Each breakout session will have a designated facilitator and note-taker. Depending on
overall size, the group will be broken down into 4 Working groups in alignment with key themes
identified, including:
1) Potential User Groups (User Perspectives): Dr. Nyaradzo Mgodi
2) Product Access and Service Delivery Models: Dr. Tsitsi Magure
3) Provider Related Issues: Cadre, Training, Service Guidelines: Dr. Edmore Munongo
4) Policy and Advocacy: Mr. Sinokuthemba Xaba
I.

Potential User Groups and their Needs (Dr. Nyaradzo Mgodi and Notetaker)
Facilitator: Ms. Ravikanthi Rapiti
Compare the attributes of topical PrEP and microbicides as different, potential HIV
prevention methods for women. For each potential user population (female sex workers,
sero-discordant couples, adolescents, women in steady relationships), discuss their HIV
prevention needs and interest in using PrEP and/or microbicides.

Sample Questions
 Based on the HIV epidemic, who (what user groups) do you think will benefit most from
tenofovir gel?
 What groups should be prioritized? What are the risks and benefits of promoting
specifically to these group(s)?
 What do you think will be the key barriers and obstacles for women who wish to access
tenofovir gel?
 What strategies can be employed to create demand? Who best to do this?
II.

Product Access & Service Delivery Models (Dr. Tsitsi Magure and Notetaker)
Facilitator: Dr. Samu Dube
Discuss potential service delivery channels for PrEP and/or microbicides and how these
could differ based on user population. What are the opportunities and challenges to
address in a program plan for tenofovir gel introduction?

Sample Questions
 Based on the HIV epidemic and health system capacity, which service settings provide
good opportunities for implementing Tenofovir gel?
 What is the feasibility of different service delivery channels?
 How will the issue of HIV testing and re-testing be addressed?
III.

Provider Perspectives: Training (Dr. Edmore Munongo and Notetaker) Facilitator:
Dr. Saiqa Mullick
Consider the types/cadres of providers who should be eligible to provider Topical PrEP.
Discuss the current state of provider knowledge, attitudes, and practices around various
HIV prevention products and services.
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Sample Questions
 What do you foresee as key challenges providers will face in offering Topical PrEP and
microbicides?
 What cadre of provider should provide these products?
 How will other SRH needs be addressed?
 Review and feedback on the Service Delivery/Facility Checklist Tool
IV.

Policy Environment and Advocacy (NAC and Notetaker) Facilitator: Ms. Victoria
James
Consider the policy, regulatory, and public health implication of introduction TVF gel.

Sample Questions
 What additional research is needed in Zimbabwe to guide implementation?
 What are the key messages to communicate to the key audiences (end users, community
members, health care providers) about Topical PrEP and microbicides?
3:00-3:30 p.m.

Group Work Begins

Resource materials and questions provided to each group
3:30-3:45 p.m.

Tea Break

Group Work Continues
4:30-5:15 p.m.

Report back

Each group facilitator summarizes key points from the discussions.
5:30

Assignments and Adjourn

DAY 2: Wednesday, May 28
8:30 a.m.

Coffee

9:00 a.m.

Recap and Synthesis of Day 1 (Dr. Samu Dube)

Facilitator synthesizes key issues to address in introduction and implementation.
9:30 a.m.

Discussion and Recommendations: (Professor Mike Chirenje)
Facilitator: Dr. Saiqa Mullick

At this point, the group is challenged with answering the following question:
What are the opportunities and challenges to address in a program implementation plan for
tenofovir gel introduction? Specifically address each of the following elements:
 Policy environment
 User perspectives and demand creation
 Service provision
 Regulatory, supply chains, logistics, etc.

20

Group makes “recommendations” around each of the key program components. Identifies gaps
and suggests ways to fill them. A comprehensive list of next steps is prepared and vetted by
meeting participants.
11:00-11:15 a.m.

Tea Break

11:15-12:15 p.m. Provider Survey (Population Council) Facilitator: Ms. Victoria James
In an effort to capture the insights and perspectives of providers, participants will be asked to
complete an anonymous self-administered questionnaire.
12:15-12:30 p.m.

Closing Remarks & Wrap Up (Dr. Owen Mugurungi)

12:30-1:30 p.m.

Lunch

Adjourn
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APPENDIX 3: Findings from Provider Survey
We were particularly interested in gathering the attitudes and opinions of provincial-level providers
and programme managers on key issues related to potential user groups, possible delivery channels,
and overall approach. To complement the rich and robust workshop discussion and thematic breakout
groups, we captured quantitatively the answers to several questions through a self-adminsitered closeended questionnaire.
A total of 58 workshop participants completed a self-administered questionnaire. Ten provinces were
represented in the repsonses. The largest number of respondents (15) were from Harare province,
followed by 8 representing national level sites. Bulawayo and Mashonaland East had 6 representatives
each. Other provinces had 2-3 participants, while Matebeleland South province had only one
representative. The workshop was successful in attracting service providers as well as programme and
facility managers. In fact, almost half (48%) of respondents identified themselves as programme or facility
managers. Workshop participants who completed the survey included: provisional nursing officers, nurse
tutors, nurse in charge, national and district medical officers, facility managers, programme managers,
advocacy officers, public health officers, STI/HIV focal persons, regional coordinators, research
coordinators, civil society representatives, journalists, and interns.
The perspectives of participants are highly instructive, as most of their institutions are already providing
prevention methods at their facilities. Here we highlight key themes from the survey.

Prevention Methods Offered
We queried workshop participants about the types of HIV prevention services they currently provide to
their clients. Information provision was cited as the most frequently offered service, with 39 respondents
(out of 56) reporting this, followed by condom promotion (38 respondents), and HIV testing and
counseling (36). Table 1 shows the type of service and number of respondents who mentioned that their
site offers that service.
Table 1: Types of HIV Prevention Methodologies and Tools Offered at Facilities
What HIV prevention methods do you offer at your facility/ies? (N-56)
More than one type of service is possible
Information

39

Condom promotion
HIV counseling and testing
STI diagnosis/treatment
PMTCT

38
36
34
29

VMMC
PEP
N/A – Not affiliated with facility
Other

25
30
12
8

Who Should Benefit from Tenofovir Gel?
All providers felt the gel would be beneficial to several groups of women, with near universal (98%)
acknowledgement that it would benefit discordant couples. Similarly, 91% of respondents felt the gel
should be made available to married women. Sex workers were viewed as a key group for the gel, with
93% suggesting that the gel should be made available to them. Women whose partners have multiple
partners were also cited by 95% of respondents as a key group. Importantly, while slightly over half of
repsondents mentioned adolescents as a population who should benefit from the gel, many would not
actually recoomend it to adolescents.
Table 2: Provider Opinions on Who Should Benefit from Tenofovir Gel
Who should benefit from tenofovir gel? (N=58)
Multiple answers were possible
Number

Percent

Discordant couples

57

98.3

Women whose partners have multiple partners

55

94.8

Sex workers

54

93.1

Married women

53

91.4

Young women (18–29 yrs)

52

89.7

Women with multiple partners

52

89.7

Women whose partners work away from home

49

84.5

Breastfeeding women

45

77.6

Women who have infrequent, high-risk sex

44

75.9

Pregnant women

42

72.4

Adolescent girls (<18 yrs)

34

58.6

Is There Any Group for Whom you Would Not Recommend Tenofovir Gel?
Nearly half (46.6%) of respondents reported having at least one group of women for whom they would not
recommend tenofovir gel. Several respondents noted that they would not recommend the product to
adolescents below age 18 years because it would be viewed as promoting promiscuity. Providing such
services to adolescents is subject to both cultural and policy constraints and is viewed as controversial.
While there was a general recognition of the vulnerability of pregnant women, there was concern about
the safety of TFV gel both for the women as well as potentially the developing fetus. Some respondents
felt that married women may have infrequent but high-risk sex (notably if their husbands have other
partners) but that the logistics and timing associated with TFV gel use may be inconvenient. Further, when
sexual relations are unplanned or unpredictable, use of coitally dependent products such as TFV gel may
pose a challenge. Finally, it was noted that TFV gel would not make sense for HIV-positive women.

Different HIV Prevention Strategies for Different Populatons
When asked whether there should be different HIV-prevention approaches for different people, responses
were mixed. On the one hand, most respondents believe that individuals need to understand HIV25

prevention options and be able to choose among them based on their own sense of risk and life
circumstances. On the other hand, there was recognition that different groups of people may be at higher
risk and face particular challenges. Most felt that recommendations should be based on risk and that
some groups of people are at higher risk than others (sero-discordant couples, sex workers). Identifying
appropriate strategies for high-risk groups will be important in terms of reduction of new cases of HIV.
Finally, a combination of prevention strategies will be needed for the effective reduction of HIV
transmission in the population.

Service Delivery Settings
The majority of respondents indicated that there are several opportunities for integrating tenofovir gel into
existing service delivery models as indicated in the table below. All 56 respondents suggested that it
would be feasible to introduce TFV gel where HCT/VCT services are provided. This was followed by 55
respondents who felt the gel can be introduced within family planning services.
Table 3. Service Delivery Settings Feasible for Providing Tenofovir Gel
Which service delivery settings do you think would be feasible for providing tenofovir gel?
More than one response was possible (N=56)
HCT/VCT services

56

Family planning services

55
54

ANC services
Primary health services
ARV treatment services

54
40

Sexual assault, rape, violence services

39

Workplace

35

Well-baby visits
VMC services
Schools

35
34
15
7

Other
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APPENDIX 4: Feedback on Tool - Checklist for Service Delivery
As an explicit part of the workshop, we sought the input of providers on a Checklist for Service
Delivery that was developed by the Population Council as part of the overall microbicide toolkit. (See
Appendix 5) The checklist was designed to be used as a guide to help clinics prepare for introduction
of microbicides, TFV gel in particular. A total of 46 workshop participants reviewed and commented on
the Checklist for Service Delivery.
Overall, most felt that the tool could go a long way in preparing for introduction, and that any introduction
effort would need to be well coordinated. Most agreed that there must be a strong commitment to
community strengthening and mobilization in order for introduction to be successful. Summary feedback on
the checklist is presented below.
The majority (68%) of respondents considered the checklist to be useful, relevant, appropriate, and
comprehensive. Comments included:


Comprehensive and relevant



User friendly; most key issues covered



Will be effective when checking on health facilities



Very useful and comprehensive



All necessary pre-introduction checks; checklist is necessary and excellent



Good because aspects of ethics are covered



Enough information that will help with quality implementation of tenofovir gel



Good because it covers important aspects such as: guidelines/protocols, IEC materials, counseling
and testing, product use and disposal; includes other preventive strategies



Several respondents noted the need for improvement. For example, comments included:
Appropriate, but this type of data-gathering tool needs to be integrated to existing ones



Need to select high-impact indicators only and wedge them into existing SRH tools



Some of the contents are duplicative of SRH checklists



Unclear as to how often checklist will be used; things may change during the course of roll-out



Will not work for shops and garages, if they are given the go ahead to distribute

Top-line Suggestions for Adaptation of Checklist:


Will need to be pilot tested; adjustments can be made after piloting the questionnaire



Programme managers/providers must be trained on how to use the checklist



Need indicator for provider competency level



Need to assess staffing levels to see if they are able to cope with additional duties, especially
record-keeping and reporting



Integrated into monitoring and evaluation tools



Other issues that should be covered:
o

Demographic data per health facility



type and level of facility offering the service
type (cadre) of healthcare provider

o

Staff training inventory

o

Pharmacy stores assessment (gel available, minimum/maximum stock calculations)

o

Staff present, date, visiting team, area of supervision, facility staff sign-off, etc.

o

Link with other SRH activities (e.g. STI registers, sexual abuse register, youth services, etc.)

Overall, the checklist was viewed positively by the majority of participants and could be pilot tested, adapted
and integrated into existing structures and monitoring processes.
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APPENDIX 5: Checklist for Service Delivery
INTRODUCING TENOFOVIR GEL:
A CHECKLIST FOR SERVICE DELIVERY
This checklist is intended for use by program managers and health providers to determine the
readiness of service delivery points to deliver tenofovir gel in a manner that promotes quality
interaction between a client and her healthcare provider. The checklist is administered
through direct observation by trained observers/researchers and can be used in one of two
ways to:
1) identify key areas requiring attention prior to initiating tenofovir gel-related services
2) support the monitoring of related services once tenofovir gel is introduced
The checklist includes the basic elements of high-quality service delivery, and is divided into
two sections:
 Section I reviews the clinical elements required for safe and effective delivery of
tenofovir gel.
 Section II reviews the program elements required for ensuring that a client makes an
informed decision regarding her options for HIV prevention and her use of tenofovir
gel if she selects that option.
Disclaimer: The checklist will be updated and revised once service delivery guidelines and
protocols for tenofovir gel are developed.

SECTION I: CLINICAL SERVICE DELIVERY
Element

Y/N

Comments

Written medical guidelines, protocols and
standards for ARV-based prevention, including
tenofovir gel, exist and are available at the site
Providers (by cadre) have been trained in the
provision of tenofovir gel
Providers have job aids that include information on
and references to tenofovir gel
Providers have IEC materials to provide
information on tenofivir gel
Providers assess client eligibility using standard
protocols and forms
Providers counsel clients about HIV testing and
repeat testing, HIV-prevention options, including
male and female condoms, and provide
instructions on use, side effects, and follow-up
required

The Population Council conducts research and delivers solutions that improve lives around the world.
Big ideas supported by evidence:
It’s our model for global change. popcouncil.org
© 2014 The Population Council, Inc.
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SECTION I: CLINICAL SERVICE DELIVERY (continued)
Providers ask clients about their reproductive
intentions and, if desired, counsel and provide a
range of contraceptive options on site or by
referral
Providers follow protocols for infection prevention
and safe disposal of medical waste
Providers give instructions to clients about how to
dispose of used applicators and/or other supplies
Client records are accurately and completely
maintained and kept confidential
Service statistics are analyzed and reported
regularly to supervisory level
A system is in place to periodically assess staff
learning and training needs
Facilities and providers receive supportive
supervision, including facilitation of problemsolving, performance expectations and feedback,
including consequences for poor quality
Facilities have the necessary equipment and
supplies to provide tenofovir gel:
 HIV test kits
 Male and female condoms
 Pelvic models (at training facilities)
 Other TBD
The facility has a system to forecast supply
requirements for resupply and it is used to submit
requests to prevent stock outs
The facility has adequate space and conditions
(temperature and humidity control; security) for
storing tenofovir gel
Facilities have adequate space to provide privacy
for confidential HIV testing and counseling on gel
use
Facilities have guidelines on internal and external
referrals to ensure comprehensive services are
provided and complicated cases are referred for
further management
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SECTION II: INFORMED DECISION-MAKING
Element
A range of HIV prevention options are available to
all groups of clients, including adolescents and
unmarried individuals
Providers tailor interactions to clients’ needs,
circumstances, and concerns
Providers treat clients with dignity and respect;
they are non-judgmental and sensitive to gender
differences and power imbalances
Providers use language that clients understand,
assess knowledge gaps, and encourage questions
to check comprehension of information provided
Providers ensure client privacy and confidentiality,
regardless of the setting
Facility ensures that linkages exist with other
departments or units within the site to facilitate
integrated services
Providers ensure that clients understand their
options and how tenofovir gel works, including
risks/benefits, proper use, partial effectiveness,
and potential for resistance
Providers emphasize the importance of condom
use as the best available means for HIV prevention
and encourage use of male and female condoms
along with tenofovir gel
Providers provide clear instructions to clients
about follow-up care, possible side effects, where
to go should problems arise, including contact
information and emergency numbers
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Y/N

Comments

